导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.43% | 3785/4773 |
| 近一周 | -1.28% | 2337/5467 |
| 近一月 | -4.28% | 1623/5421 |
| 近一季 | 0.30% | 955/5238 |
| 近半年 | -7.62% | 3497/4931 |
| 近一年 | -16.66% | 3795/4400 |
| 近两年 | 29.49% | 2269/2954 |
| 近三年 | 16.17% | 1589/2253 |
| 成立以来 | -1.74% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.30% 4224/4961 |
-9.03% 3937/5312 |
- - |
- - |
| 2025 | 26.83% 1602/4813 |
15.66% 164/3635 |
3.61% 977/4076 |
14.36% 2917/4524 |
-7.46% 3800/4813 |
| 2024 | 10.13% 1435/3463 |
-5.98% 1985/2808 |
3.62% 261/3014 |
17.89% 1105/3129 |
-4.11% 2440/3463 |
| 2023 | -14.67% 1613/2656 |
-3.15% 2068/2280 |
-1.23% 454/2385 |
-8.50% 1704/2515 |
-2.51% 483/2655 |
| 2022 | -10.06% 195/2207 |
-9.94% 369/1919 |
6.86% 590/2016 |
-17.18% 1560/2113 |
12.85% 119/2208 |
| 2021 | -14.78% 1150/1822 |
2.12% 227/1255 |
1.95% 1026/1330 |
-11.92% 1281/1466 |
-7.07% 1562/1822 |
| 2020 | 7.74% 864/1250 |
-12.99% 911/1028 |
11.03% 749/1067 |
0.14% 1045/1164 |
11.36% 548/1184 |
| 2019 | 11.97% 719/1092 |
10.65% 716/739 |
0.16% 185/788 |
-5.41% 794/850 |
6.81% 542/918 |
| 2018 | - - |
- - |
- - |
-1.19% 236/660 |
-7.31% 63/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安CES港股通ETF联接C VS. 长安沪深300非周期A(740101) |